ArticleOncoimmunology2015
Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma.
Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02654288 (Dynamic Changes of the Serum Level of Immunoglobulin G4), which is not on this map. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Dynamic Changes of the Serum Level of Immunoglobulin G4(IgG4) and Interleukin-10(IL-10) in the Patients of Pancreatic Cancer After Gemcitabine-based Chemotherapy
Who cites it
47 citing papers in PubMed, 66 citations in OpenAlex.
- B cells and humoral immunity in melanoma: regulatory and autoimmune-like features and implications for immunotherapy.Oncoimmunology · 2026Review
- Regulation of follicular helper T cell subset differentiation in health and disease.Journal of molecular medicine (Berlin, Germany) · 2026Review
- Tumor-infiltrating B cells evolve towards interferon-rich trajectories aligned with immunotherapy in melanoma.Journal of experimental & clinical cancer research : CR · 2026Article
- Phenotypic, functional, prognostic and predictive significance of B-cell and antibody responses in human melanoma: a scoping review.The British journal of dermatology · 2026Article
- Review
- Adaptive immune changes in colorectal cancer: a focus on T and B cell activation genes.Discover oncology · 2025Article
- Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma.Journal for immunotherapy of cancer · 2025Article
- Review
- The relationship between immunoglobulin G4-related disease and malignancy.Reumatologia · 2025Article
- Circulating memory B-cell receptor repertoire analysis identifies novel candidate antibodies against metastatic melanoma in immunotherapy-responsive patients.Frontiers in immunology · 2025Article
- Unraveling the dual roles of tumor-infiltrating antibodies in solid tumors: friend or foe in the tumor microenvironment?Frontiers in immunology · 2025Review
- Determinants of resistance and response to melanoma therapy.Nature cancer · 2024Review
- B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors.Journal for immunotherapy of cancer · 2024Review
- IgG4 autoantibodies and autoantigens in the context of IgG4-autoimmune disease and IgG4-related disease.Frontiers in immunology · 2024Review
- IgG4-mediated M2 macrophage polarization in tertiary lymphoid structures of esophageal cancer: implications for immunosuppression.Frontiers in immunology · 2024Article
- Elevated IgE Levels-An Allergy or an Underlying Inborn Error of Immunity in Children with Recurrent Infections?Antibodies (Basel, Switzerland) · 2023Article
- The unique properties of IgG4 and its roles in health and disease.Nature reviews. Immunology · 2023Review
- Serum immunoglobulin and the threshold of Fc receptor-mediated immune activation.Biochimica et biophysica acta. General subjects · 2023Review
- B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma.Nature communications · 2023Article
- Evaluation of multiple immune cells and patient outcomes in esophageal squamous cell carcinoma.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 7 institutions in 3 countries.
Panagiotis KaragiannisSt. John's Institute of Dermatology; Division of Genetics and Molecular Medicine; Faculty of Life Sciences and Medicine; King's College London & NIHR Biomedical Research Centre at Guy's and St. Thomas' Hospitals and King's College London; Guy's Hospital; King's College London ; London, UK ; University Hospital of Hamburg Eppendorf; Department of Oncology; Hematology and Stem Cell Transplantation ; Hamburg, Germany.
Federica VillanovaSt. John's Institute of Dermatology; Division of Genetics and Molecular Medicine; Faculty of Life Sciences and Medicine; King's College London & NIHR Biomedical Research Centre at Guy's and St. Thomas' Hospitals and King's College London; Guy's Hospital; King's College London ; London, UK.
Debra H JosephsSt. John's Institute of Dermatology; Division of Genetics and Molecular Medicine; Faculty of Life Sciences and Medicine; King's College London & NIHR Biomedical Research Centre at Guy's and St. Thomas' Hospitals and King's College London; Guy's Hospital; King's College London ; London, UK ; Department of Research Oncology; Division of Cancer Studies; Faculty of Life Sciences and Medicine; King's College London; Guy's Hospital ; London, UK.
Isabel CorreaSt. John's Institute of Dermatology; Division of Genetics and Molecular Medicine; Faculty of Life Sciences and Medicine; King's College London & NIHR Biomedical Research Centre at Guy's and St. Thomas' Hospitals and King's College London; Guy's Hospital; King's College London ; London, UK.
Mieke Van HemelrijckKing's College London; Faculty of Life Sciences and Medicine; Division of Cancer Studies; Cancer Epidemiology Group; Guy's Hospital; London, UK.
Carl HobbsWolfson Center for Age-Related Diseases; King's College London ; London, UK.
Louise SaulSt. John's Institute of Dermatology; Division of Genetics and Molecular Medicine; Faculty of Life Sciences and Medicine; King's College London & NIHR Biomedical Research Centre at Guy's and St. Thomas' Hospitals and King's College London; Guy's Hospital; King's College London ; London, UK ; Department of Research Oncology; Division of Cancer Studies; Faculty of Life Sciences and Medicine; King's College London; Guy's Hospital ; London, UK.
Isioma U EgbuniweSt. John's Institute of Dermatology; Division of Genetics and Molecular Medicine; Faculty of Life Sciences and Medicine; King's College London & NIHR Biomedical Research Centre at Guy's and St. Thomas' Hospitals and King's College London; Guy's Hospital; King's College London ; London, UK.
Isabella TosiSt. John's Institute of Dermatology; Division of Genetics and Molecular Medicine; Faculty of Life Sciences and Medicine; King's College London & NIHR Biomedical Research Centre at Guy's and St. Thomas' Hospitals and King's College London; Guy's Hospital; King's College London ; London, UK.
Kristina M IlievaSt. John's Institute of Dermatology; Division of Genetics and Molecular Medicine; Faculty of Life Sciences and Medicine; King's College London & NIHR Biomedical Research Centre at Guy's and St. Thomas' Hospitals and King's College London; Guy's Hospital; King's College London ; London, UK ; Breakthrough Breast Cancer Research Unit; Department of Research Oncology; Guy's Hospital; King's College London School of Medicine ; London, United Kingdom.
Emma KentSt. John's Institute of Dermatology; Division of Genetics and Molecular Medicine; Faculty of Life Sciences and Medicine; King's College London & NIHR Biomedical Research Centre at Guy's and St. Thomas' Hospitals and King's College London; Guy's Hospital; King's College London ; London, UK.
Eduardo CalonjeSkin Tumor Unit; St. John's Institute of Dermatology; Guy's Hospital, King's College London and Guy's and St Thomas' NHS Trust ; London, UK.
Mark HarriesClinical Oncology; Guy's and St. Thomas's NHS Foundation Trust , London, UK.
Ian FentimanDepartment of Research Oncology; Division of Cancer Studies; Faculty of Life Sciences and Medicine; King's College London; Guy's Hospital ; London, UK.
Joyce Taylor-PapadimitriouDepartment of Research Oncology; Division of Cancer Studies; Faculty of Life Sciences and Medicine; King's College London; Guy's Hospital ; London, UK.
Joy BurchellDepartment of Research Oncology; Division of Cancer Studies; Faculty of Life Sciences and Medicine; King's College London; Guy's Hospital ; London, UK.
James F SpicerDepartment of Research Oncology; Division of Cancer Studies; Faculty of Life Sciences and Medicine; King's College London; Guy's Hospital ; London, UK.
Katie E LacySt. John's Institute of Dermatology; Division of Genetics and Molecular Medicine; Faculty of Life Sciences and Medicine; King's College London & NIHR Biomedical Research Centre at Guy's and St. Thomas' Hospitals and King's College London; Guy's Hospital; King's College London ; London, UK ; Skin Tumor Unit; St. John's Institute of Dermatology; Guy's Hospital, King's College London and Guy's and St Thomas' NHS Trust ; London, UK.
Frank O NestleSt. John's Institute of Dermatology; Division of Genetics and Molecular Medicine; Faculty of Life Sciences and Medicine; King's College London & NIHR Biomedical Research Centre at Guy's and St. Thomas' Hospitals and King's College London; Guy's Hospital; King's College London ; London, UK.
Sophia N KaragiannisSt. John's Institute of Dermatology; Division of Genetics and Molecular Medicine; Faculty of Life Sciences and Medicine; King's College London & NIHR Biomedical Research Centre at Guy's and St. Thomas' Hospitals and King's College London; Guy's Hospital; King's College London ; London, UK.
King's College London · GBGuy's Hospital · GBSt Thomas' Hospital · GBEppendorf (Germany) · DEGuy's and St Thomas' NHS Foundation Trust · GBSkin Cancer Foundation · USSt. John's University · US
Funding
Cancer Research UK C30122/A11527Medical Research Council MR/L023091/1
Abstract
Emerging evidence suggests pathological and immunoregulatory functions for IgG4 antibodies and IgG4
Indexed as
B cellsbiomarkercancer inflammationhumoral responseIgG4immunomodulationimmunomonitoringimmunosuppressionmelanomaprognosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT02654288ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.